Low free T3 levels within the reference range independently predict cardiovascular mortality in the general population

2018 ◽  
Author(s):  
Joao Sergio Neves ◽  
Catarina Viegas Dias ◽  
Lia Leitao ◽  
Miguel Bigotte Vieira ◽  
Rita Magrico ◽  
...  
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Reference Range ◽  
Free T3

scholarly journals Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort

2019 ◽  
Vol 40 (33) ◽  
pp. 2813-2824 ◽  
Author(s):  
Katrine L Rasmussen ◽  
Anne Tybjærg-Hansen ◽  
Børge G Nordestgaard ◽  
Ruth Frikke-Schmidt
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Cancer Mortality ◽  
Plasma Levels ◽  
Apoe Genotype ◽  
High Plasma ◽  
Increased Risk ◽  
Specific Mortality ◽  
General Population Cohort ◽  
Low Levels

Abstract Aims To determine whether plasma apoE levels and APOE genotype are associated with all-cause and cause-specific mortality. Methods and results Using a prospective cohort design with 105 949 white individuals from the general population, we tested the association between plasma apoE at study enrolment and death during follow-up, and whether this was independent of APOE genotype. We confirmed the well-known association between APOE genotypes and mortality. For all-cause, cardiovascular, and cancer mortality, high levels of apoE were associated with increased risk, while for dementia-associated mortality low levels were associated with increased risk. For the highest vs. the fifth septile of plasma apoE, hazard ratios (HRs) were 1.20 (95% confidence interval 1.12–1.28) for all-cause mortality, 1.28 (1.13–1.44) for cardiovascular mortality, and 1.18 (1.05–1.32) for cancer mortality. Conversely, for the lowest vs. the fifth septile the HR was 1.44 (1.01–2.05) for dementia-associated mortality. Results were similar in analyses restricted to APOE ɛ33 carriers. Examining genetically determined plasma apoE, a 1 mg/dL increase conferred risk ratios of 0.97 (0.92–1.03) for cardiovascular mortality and 1.01 (0.95–1.06) for cancer mortality, while a 1 mg/dL decrease conferred a risk ratio of 1.70 (1.36–2.12) for dementia-associated mortality. Conclusion High plasma levels of apoE were associated with increased all-cause, cardiovascular, and cancer mortality, however of a non-causal nature, while low levels were causally associated with increased dementia-associated mortality.

Individual 6-year systolic blood pressure change and impact on cardiovascular mortality in a French general population

2015 ◽  
Vol 30 (1) ◽  
pp. 18-23 ◽  
Author(s):  
B Pannier ◽  
F Thomas ◽  
O Hanon ◽  
S Czernichow ◽  
C Lemogne ◽  
...  
Keyword(s):  
Blood Pressure ◽  
General Population ◽  
Systolic Blood Pressure ◽  
Cardiovascular Mortality ◽  
Pressure Change ◽  
Blood Pressure Change

scholarly journals Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis

2014 ◽  
Vol 99 (6) ◽  
pp. 2018-2029 ◽  
Author(s):  
Nicholas A. Tritos ◽  
Gudmundur Johannsson ◽  
Márta Korbonits ◽  
Karen K. Miller ◽  
Ulla Feldt-Rasmussen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
General Population ◽  
Outcome Measures ◽  
Cardiovascular Mortality ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
World Health ◽  
Gh Replacement

Context: GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD). Objective: Our objective was to examine the effectiveness and safety of GH replacement in acroGHD. Design: This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database). Setting: Data were extracted from a pharmaco-epidemiological survey of >16 000 GHD adults from 31 countries. Patients: The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease). Outcome Measures: Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints. Results: Median GH dose was 0.3 mg/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA (standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed/expected cases [95% confidence interval] = 1.32 [0.70–2.25]) and lower in NFPA [observed/expected = 0.58 [0.48–0.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA. Conclusions: GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD.

Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial

2006 ◽  
Vol 24 (25) ◽  
pp. 4184-4189 ◽  
Author(s):  
Suzie J. Otto ◽  
Fritz H. Schröder ◽  
Harry J. de Koning
Keyword(s):  
Prostate Cancer ◽  
General Population ◽  
Cancer Patients ◽  
Cardiovascular Mortality ◽  
Randomized Study ◽  
Primary Treatment ◽  
Treatment Modalities ◽  
Prostate Cancer Treatment ◽  
Standardized Mortality Ratios

Purpose To estimate the risk of cardiovascular disease (CVD) mortality in prostate cancer patients in the Rotterdam section of European Randomized Study of Screening for Prostate Cancer, in both arms, and to compare this with the risk in the general population. Methods Standardized mortality ratios (SMRs) of cardiovascular mortality for 2,211 prostate cancer patients were calculated including analyses for treatment subgroups (surgery, radiotherapy, watchful waiting, and hormone therapy). Cardiovascular mortality was defined as death as a result of all CVD and as a result of coronary heart disease, acute myocardial infarction, other diseases of the heart, and cerebrovascular accidents. The prevalence of self-reported comorbidities at entry of the trial was evaluated as well. Results After a mean follow-up of 5.5 years, 258 prostate cancer patients (12%) had died. The SMR of all-cause mortality was 0.90 (95% CI, 0.79 to 1.01). The risk for cardiovascular mortality was low compared with that in the general population; the SMRs varied between 0.37 and 0.49. Low cardiovascular mortality risks were also seen within each treatment subgroup. CVD was the most frequently self-reported comorbidity at entry and prostate cancer patients undergoing radical prostatectomy reported the lowest rates (24%) compared with those receiving other therapies (40% to 42%). Conclusion Although some self-selection has occurred, prostate cancer treatment did not increase the risk of dying as a result of cardiovascular causes in our cohort. The risk was significantly lower for all primary treatment modalities, suggesting that less emphasis should be put on CVD as a contraindication for aggressive (surgical) treatment for prostate cancer patients.

Sign in / Sign up

Export Citation Format

Share Document